NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.
Why now
Thesis: Research funding cuts stall pediatric cancer trials
Catalyst to watch: Congressional funding decisions
Main risk: Patients lose access to experimental therapy
Why it matters
NIH funding cuts delaying a pediatric cancer trial illustrate how federal research reductions slow drug development timelines.
Details
A delayed clinical trial underscores the stakes of federal research funding cuts for children with DIPG, a deadly brain tumor with few treatment options.
Sources
- cnbc · 2026-09-25 11:00 UTC